Celltrion's YUFLYMA® (adalimumab-aaty) receives FDA interchangeability designation for all its approved dosage forms and strengths YUFLYMA® (adalimumab-aaty) is a high-concentration (100mg/mL) and citrate-free formulation of Humira® (adalimumab)… CISION PRNewswireMay 24, 2025
Global Times: Why China's economy so stable despite external challenges? BEIJING, May 24, 2025 /PRNewswire/ — "In April, China’s economic data showed… CISION PRNewswireMay 23, 2025
Press Release Robots and Human-Centric AI Dazzle at Opening of BEYOND Expo 2025 Pioneering Asian tech unveiled as industry leaders call for global cooperation MACAO,… CISION PRNewswireMay 23, 2025
Press Release TWSC Debuts at COMPUTEX 2025: Empowering AI with Full-Stack Storage Solutions TAIPEI, May 23, 2025 /PRNewswire/ — From May 20 to 23, 2025,… CISION PRNewswireMay 23, 2025
Press Release MBZUAI Launches Institute of Foundation Models and Establishes Silicon Valley AI Lab SAN FRANCISCO, May 23, 2025 /PRNewswire/ — Mohamed bin Zayed University of… CISION PRNewswireMay 23, 2025
Press Release LILYSILK Unveils Breathable, Stretchable, and Machine-Washable Silk Jersey Collection for Summer 2025 NEW YORK, May 23, 2025 /PRNewswire/ — LILYSILK, the world’s leading silk… CISION PRNewswireMay 23, 2025
Mabwell Announces Clinical Data of Multiple ADCs to be presented at 2025 ASCO Annual Meeting SHANGHAI, May 23, 2025 /PRNewswire/ — Mabwell (688062.SH), an innovation-driven biopharmaceutical company… CISION PRNewswireMay 23, 2025
Press Release Trading With Confidence: Bybit Offers Zero-Loss Coverage and Educational Rewards DUBAI, UAE, May 23, 2025 /PRNewswire/ — Bybit, the world’s second-largest cryptocurrency… CISION PRNewswireMay 23, 2025
